SCLX Stock Overview
Focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Scilex Holding Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.01 |
| 52 Week High | US$80.50 |
| 52 Week Low | US$3.60 |
| Beta | 1.11 |
| 1 Month Change | -41.58% |
| 3 Month Change | -67.45% |
| 1 Year Change | -84.63% |
| 3 Year Change | -98.88% |
| 5 Year Change | n/a |
| Change since IPO | -98.84% |
Recent News & Updates
Recent updates
Scilex Holding Company (NASDAQ:SCLX) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Mar 04
Analysts Just Shaved Their Scilex Holding Company (NASDAQ:SCLX) Forecasts Dramatically
Jun 14It's Down 33% But Scilex Holding Company (NASDAQ:SCLX) Could Be Riskier Than It Looks
Apr 24Scilex Holding Company's (NASDAQ:SCLX) 35% Price Boost Is Out Of Tune With Revenues
Feb 28Risks To Shareholder Returns Are Elevated At These Prices For Scilex Holding Company (NASDAQ:SCLX)
Dec 21Shareholder Returns
| SCLX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -26.3% | -6.8% | -0.3% |
| 1Y | -84.6% | -9.8% | 8.1% |
Return vs Industry: SCLX underperformed the US Pharmaceuticals industry which returned -9.8% over the past year.
Return vs Market: SCLX underperformed the US Market which returned 8.1% over the past year.
Price Volatility
| SCLX volatility | |
|---|---|
| SCLX Average Weekly Movement | 18.3% |
| Pharmaceuticals Industry Average Movement | 10.9% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: SCLX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SCLX's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 115 | Jaisim Shah | www.scilexholding.com |
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia.
Scilex Holding Company Fundamentals Summary
| SCLX fundamental statistics | |
|---|---|
| Market cap | US$20.99m |
| Earnings (TTM) | -US$72.81m |
| Revenue (TTM) | US$56.59m |
0.4x
P/S Ratio-0.3x
P/E RatioIs SCLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCLX income statement (TTM) | |
|---|---|
| Revenue | US$56.59m |
| Cost of Revenue | US$16.69m |
| Gross Profit | US$39.90m |
| Other Expenses | US$112.71m |
| Earnings | -US$72.81m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -13.91 |
| Gross Margin | 70.51% |
| Net Profit Margin | -128.66% |
| Debt/Equity Ratio | -22.1% |
How did SCLX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 09:55 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Scilex Holding Company is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Jason Kolbert | D. Boral Capital LLC. |